Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes

Trial Profile

Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2016

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LIRA-NAFLD/LIP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Oct 2016 Results assessing effect of liraglutide therapy on liver fat content published in the Journal of Clinical Endocrinology and Metabolism
    • 12 Oct 2016 Primary endpoint effect of liraglutide on fatty liver content evaluated by proton-spectroscopy has been met. (Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top